Nature:发现HIV病毒躲避免疫系统杀伤的新方式

2019-04-16 不详 细胞

一项耶鲁大学领导的研究团队发现了HIV用于应对免疫系统攻击而生存下来的另一个分子机制,这项发现将影响科学家们开发有效对抗HIV/AIDS疫苗的思路。

一项耶鲁大学领导的研究团队发现了HIV用于应对免疫系统攻击而生存下来的另一个分子机制,这项发现将影响科学家们开发有效对抗HIV/AIDS疫苗的思路。

HIV病毒会在其表面形成一种被称为三聚体的具有特殊形状的结构,病毒会利用这些结构去粘附、感染细胞并产生更多的HIV病毒。为了避开免疫系统的攻击,这些三聚体可以随着时间改变形状,因此具有三种不同的构象。科学家们现在正在开发的疫苗就旨在靶向其中一种构象,从而引发机体对抗病毒的免疫反应。但是这项最新发表在《Nature》上的研究表明HIV也许可以通过藏在另一个三聚体构象(被称为State 1)中躲避免疫系统的检测。

据研究人员报道,病人会通过产生广泛的中和抗体来对抗HIV,其中大多数抗体识别的是处于State 1构象的病毒。

“如果这些抗体可以结合处于State 1构象的三聚体,那么疫苗中的任何免疫原都可以识别这个构象。”该研究共同通讯作者、微生物病理学教授Walther Mothes说道。“但是令人惊讶的是,现有的免疫原只识别State 2构象,会产生State 2构象特异性的抗体。”

Mothe的实验室计划进一步探索State 1构象的结构,这将有助于开发出可以识别这一构象的免疫原。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2070202, encodeId=398e20e0202a9, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Dec 19 19:21:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883678, encodeId=eb0918836e889, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 25 17:21:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364918, encodeId=cd323649181f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Apr 19 23:01:43 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412640, encodeId=97181412640f1, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Thu Apr 18 09:21:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364820, encodeId=2430364820bd, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Wed Apr 17 23:36:23 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2070202, encodeId=398e20e0202a9, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Dec 19 19:21:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883678, encodeId=eb0918836e889, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 25 17:21:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364918, encodeId=cd323649181f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Apr 19 23:01:43 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412640, encodeId=97181412640f1, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Thu Apr 18 09:21:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364820, encodeId=2430364820bd, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Wed Apr 17 23:36:23 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2020-01-25 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2070202, encodeId=398e20e0202a9, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Dec 19 19:21:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883678, encodeId=eb0918836e889, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 25 17:21:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364918, encodeId=cd323649181f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Apr 19 23:01:43 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412640, encodeId=97181412640f1, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Thu Apr 18 09:21:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364820, encodeId=2430364820bd, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Wed Apr 17 23:36:23 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-19 医者仁心5538

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2070202, encodeId=398e20e0202a9, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Dec 19 19:21:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883678, encodeId=eb0918836e889, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 25 17:21:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364918, encodeId=cd323649181f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Apr 19 23:01:43 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412640, encodeId=97181412640f1, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Thu Apr 18 09:21:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364820, encodeId=2430364820bd, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Wed Apr 17 23:36:23 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2070202, encodeId=398e20e0202a9, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Dec 19 19:21:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883678, encodeId=eb0918836e889, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 25 17:21:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364918, encodeId=cd323649181f, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Apr 19 23:01:43 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412640, encodeId=97181412640f1, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Thu Apr 18 09:21:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364820, encodeId=2430364820bd, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Wed Apr 17 23:36:23 CST 2019, time=2019-04-17, status=1, ipAttribution=)]
    2019-04-17 清幽蓝燕yan

    涨知识

    0

相关资讯

ViiV Healthcare和荷兰Radboud大学合作寻找HIV药物新靶标

ViiV Healthcare宣布与荷兰Radboud大学医疗中心合作,以寻找艾滋病毒的新药物目标。ViiV将为该中心提供专门资金,以提高人类功能基因组学项目(HFGP)在HIV疾病领域的探索。

Lancet HIV :重组腺病毒PG9-HIV疫苗的安全性研究

重组腺病毒HIV疫苗是安全的,但需要进一步考察PG9基因载体类型

JAMA:HIV接触前预防与高危人群性传播感染风险

男同性恋和双性恋者接受HIV接触前预防后,细菌性性传播感染风险增加

第13届美国艾滋病治疗会议:HIV新药SYMTUZA的安全性和有效性数据

强生公司近日公布了SYMTUZA®(darunavir 800 mg,cobicistat 150 mg,emtricitabine 200 mg和tenofovir alafenamide 10 mg)​的​48周数据(DIAMOND研究)显示,大多数HIV患者在48周内无法检测到病毒载量。该研究的次要终点还显示,97%的患者表示他们对治疗感到满意。

美国完成首例HIV携带者间活体肾脏移植

美国约翰斯·霍普金斯大学医院28日宣布3天前完成世界首例人类免疫缺陷病毒(HIV)、即艾滋病病毒携带者之间的活体肾脏移植手术。

2018 BHIVA指南:妊娠和产后HIV的管理

2018年版英国艾滋病协会(BHIVA)妊娠和产后HIV的管理的主要目的是针对HIV感染女性在妊娠和产后期间的质量和管理提供指导建议,包括应用抗逆转录治疗预防母婴传播,分娩的管理,新生儿管理和产后管理等。